If found to be safe and efficacious in SCN1B-associated DEE, fenfluramine could be used in early infancy to reduce incidence of developmental disability, status epilepticus and prolonged hospitalizations. This evidence concerns the gene SCN1B and developmental and epileptic encephalopathy.